Page 4 - Microba Life Sciences News Today

EQS-News: SYNLAB AG / Key word(s): Alliance/Market Launch SYNLAB AG: SYNLAB and Microba reinforce their combined expertise and expand...

Investegate announcements from SYNLAB AG, SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME

/PRNewswire/ -- The Microbiome Therapeutics Innovation Group (MTIG), an independent 501(c)(6) coalition of companies leading the research and development of...

The Global Epigenetics Market size is expected to reach $2. 9 billion by 2028, rising at a market growth of 14. ...

NYSE-listed Ginkgo Bioworks (NYSE: DNA) has entered into a technical development agreement with ASX-listed Microba Life Sciences (ASX: MAP). Firm: MinterEllison (Ginkgo Bioworks). Deal: The developm

WASHINGTON, April 25, 2022 /PRNewswire/ -- The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coali...

Gut health business Microba Life Sciences Ltd (ASX: MAP) has successfully listed on the Australian Securities Exchange, in an initial public offering that raised $30 million. Firm: Thomson Geer (Micro

Appointment of Professor Trent Munro as Senior Vice President of Therapeutics.Professor Munro has over 25 years’ research and development experience, including with multinational biopharmaceutical company Amgen based in California, United States.Professor Munro has recently held several leadership roles in Australia...

Microba Life Sciences Limited lists on the ASX today under code MAP after raising $30 million. The market capitalisation is ~$123 million (on an undiluted basis) at the Offer price of $0.45 per share.Microba is a commercial-stage company delivering gut microbiome testing services globally and driving the discovery o...

The Brisbane-based company was founded to commercialize a technology for microbial analysis, with a focus on the human gut microbiome.